Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Left Ventricular Dysfunction Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

The STandard Versus ImAging SuBstrate Aided Ablation in Severe Left VEntricular Dysfunction VT.

NCT05828667
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

NCT03785405
View directory record Official record
Conditions
Heart Failure
Interventions
sacubitril/valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
15
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 7, 2026, 3:15 AM EDT
Not yet recruiting Not applicable Interventional

Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)

NCT07776964
View directory record Official record
Conditions
Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer, Multiple Myeloma
Interventions
Mobile Cardiac Telemetry, Wearable Cardiac Monitor
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Enrolling by invitation No phase listed Observational

Federated Learning for Point-of-Care Cardiac Ultrasound

NCT07800962
View directory record Official record
Conditions
Ventricular Dysfunction, Left, Ventricular Function, Left, Echocardiography, Ultrasonography, Point-of-Care Systems, Heart Function Tests, Stroke Volume, Federated Learning, Machine Learning, Artificial Intelligence (AI), Deep Learning, Neural Networks, Computer, Image Interpretation, Computer-Assisted, Diagnosis, Computer-Assisted, Sensitivity and Specificity, ROC Curve
Interventions
Focused Cardiac Point-of-Care Ultrasonography, FL-POCUS Federated Machine-Learning Analysis System
Diagnostic Test · Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Recruiting No phase listed Observational

STICH3C Cardiac Magnetic Resonance Observational Study

NCT07133984
View directory record Official record
Conditions
Ischemic Left Ventricle Systolic Dysfunction, Multivessel Coronary Artery Disease
Interventions
Cardiac Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Brooklyn, New York • Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2 Interventional

Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

NCT00259038
View directory record Official record
Conditions
Heart Failure, Congestive, Heart Decompensation, Left Ventricular Failure, Myocardiopathies, Systolic or Diastolic Left Ventricular Dysfunction
Interventions
Carperitide, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Huntsville, Alabama • Los Angeles, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 4 Interventional

Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.

NCT01800292
View directory record Official record
Conditions
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Interventions
sildenafil
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 4 Interventional Results available

Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.

NCT01936649
View directory record Official record
Conditions
Heart Failure (HF), Ventricular Dysfunction, Left
Interventions
AdreView (Iobenguane I 123 Injection)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fat Metabolism in Pregnancy and Neonatal Heart Function in Diabetes

NCT01346527
View directory record Official record
Conditions
Type 2 Diabetes, Pregnancy
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional

Echo-guided Hemodynamic Management Strategy in Elderly Patients Undergoing Noncardiac Surgery

NCT01780727
View directory record Official record
Conditions
Ventricular Dysfunction, Left, Major Adverse Cardiac Events
Interventions
EGHEM
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
70 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056
View directory record Official record
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Not applicable Interventional Results available

The Use of CoSeal (Sealant Agent) in Patients During Left Ventricular Assist Device Surgery

NCT01605019
View directory record Official record
Conditions
Heart Failure, Ventricular Dysfunction
Interventions
CoSeal, BioGlue® Surgical Adhesive
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional Results available

Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation

NCT00121472
View directory record Official record
Conditions
Heart Failure, Congestive, Ventricular Dysfunction, Cardiomyopathies
Interventions
Thoratec HeartMate II Left Ventricular Assist System (LVAS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

NCT01458405
View directory record Official record
Conditions
Myocardial Infarction
Interventions
CAP-1002 Allogeneic Cardiosphere-Derived Cells, Placebo
Biological · Drug
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional

The IMPULSE Study: Pilot

NCT02044471
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Remote Ischemic Conditioning (using Sphygmomanometer)
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

NCT02013037
View directory record Official record
Conditions
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational

The Product Surveillance Registry REVERSE Post Approval Study

NCT01660035
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
102
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Sep 7, 2026, 3:15 AM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085
View directory record Official record
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
29 Days to 17 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational

Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation

NCT02428894
View directory record Official record
Conditions
Ventricular Dysfunction, Left
Interventions
LVAD
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analysis of Heart Muscle Function Following Exercise in Patients With Heart Disease

NCT00001528
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

NCT00768066
View directory record Official record
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo
Biological
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function

NCT00405639
View directory record Official record
Conditions
Heart Failure, Asymptomatic Systolic Dysfunction
Interventions
Nesiritide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2014 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational

Predicting Response to Cardiac Resynchronization Therapy in Heart Failure

NCT00359372
View directory record Official record
Conditions
Heart Failure, Left Ventricular Dysfunction
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

NCT01065454
View directory record Official record
Conditions
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 7, 2026, 3:15 AM EDT